A Clinical Trial on the Antipsychotic Properties of Cannabidiol

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

July 31, 2008

Conditions
SchizophreniaPsychotic Disorders
Interventions
DRUG

Placebo/Cannabidiol

600 mg/day, oral, capsules, 2 weeks, than cross-over

DRUG

Cannabidiol/Placebo

600 mg/day, oral, capsules, 2 weeks, than cross-over

Trial Locations (1)

50924

University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

collaborator

Coordinating Centre for Clinical Trials Cologne

OTHER

lead

University of Cologne

OTHER